Vimarsana
Biggest News Aggregation in the World

Page 13 - Hartmutj Ehrlich News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Hartmutj Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Hartmutj Ehrlich Today - Breaking & Trending Today

Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference - Vimarsana News

Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference

DGAP-News: ABIVAX / Key word(s): Conference15.12.2021 / 18:30 The issuer is solely responsible for the content of this announcement.Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference Abivax's presentation at the virtual J.P. Morgan Healthcare Conference scheduled for Thursday, January 13, 20...

ABIVAX: Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis - Vimarsana News

ABIVAX: Abivax Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

End-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)PARIS, FRANCE / ACCESSWIRE /

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis - Vimarsana News

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

Abivax SA , a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today announced that... | December 1, 2021

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulce - Vimarsana News

Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulce

DGAP-News: ABIVAX / Key word(s): Study01.12.2021 / 19:30 The issuer is solely responsible for the content of this announcement.Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitisEnd-of-phase-2 response from the US regulatory agency (FDA) provides guidanc...

ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis - Vimarsana News

ABIVAX: ABX464 shows excellent long-term efficacy data in Abivax's phase 2b maintenance Trial in ulcerative colitis

Impressive clinical remission in 58.4% (ITT) of 101 patients after 48 weeks of once-daily oral 50mg ABX464, showing both maintained as well as further improved efficacyFavorable safety and tolerability